Differential mechanism of NF-κB inhibition by two glucocorticoid receptor modulators in rheumatoid arthritis synovial fibroblasts

Arthritis and Rheumatism

Volumn 60, Issue 11, 2009, Pages 3241-3250

  Gossye, Valerie ^a   Elewaut, Dirk ^b   Bougarne, Nadia ^a   Bracke, Debby ^a   Van Calenbergh, Serge ^a   Haegeman, Guy ^a   De Bosscher, Karolien ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DNA; GLUCOCORTICOID RECEPTOR ANTAGONIST; I KAPPA B ALPHA; I KAPPA B KINASE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOPROTEIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN TRANSPORT; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DEXAMETHASONE; EIF-2 KINASE; FIBROBLASTS; GLUCOCORTICOIDS; HUMANS; I-KAPPA B KINASE; INTERLEUKIN-1BETA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NF-KAPPA B; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, GLUCOCORTICOID; RNA, SMALL INTERFERING; SYNOVIAL MEMBRANE;

EID: 70350523976     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24963     Document Type: Article

References (51)

1. Knedla A, Neumann E, Muller-Ladner U. Developments in the synovial biology field 2006. Arthritis Res Ther 2007;9:209-216
2. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2:473-488
3. Muller-Ladner U, Ospelt C, Gay S, Distler O, Pap T. Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts. Arthritis Res Ther 2007;9:223-233
4. Muller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996;149:1607-1615 (Pubitemid 26363967)
5. Smith TJ. Insights into the role of fibroblasts in human autoimmune diseases. Clin Exp Immunol 2005;141:388-397 (Pubitemid 41075861)
6. Abeles AM, Pillinger MH. The role of the synovial fibroblast in rheumatoid arthritis: cartilage destruction and the regulation of matrix metalloproteinases. Bull NYU Hosp Jt Dis 2006;64:20-24
7. Karouzakis E, Neidhart M, Gay RE, Gay S. Molecular and cellular basis of rheumatoid joint destruction. Immunol Lett 2006;106: 8-13. (Pubitemid 44093056)
8. Mor A, Abramson SB, Pillinger MH. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 2005;115:118-128 (Pubitemid 40693079)
9. Li X, Makarov SS. An essential role of NF-κB in the "tumor-like" phenotype of arthritic synoviocytes. Proc Natl Acad Sci U S A 2006;103:17432-17437
10. Asahara H, Asanuma M, Ogawa N, Nishibayashi S, Inoue H. High DNA-binding activity of transcription factor NF-κB in synovial membranes of patients with rheumatoid arthritis. Biochem Mol Biol Int 1995;37:827-832 (Pubitemid 26177939)
11. Vincenti MP, Coon CI, Brinckerhoff CE. Nuclear factor κB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1β-stimulated synovial fibroblasts. Arthritis Rheum 1998;41:1987-1994
12. Miyazawa K, Mori A, Yamamoto K, Okudaira H. Transcriptional roles of CCAAT/enhancer binding protein-β, nuclear factor-κB, and C-promoter binding factor 1 in interleukin (IL)-1β-induced IL-6 synthesis by human rheumatoid fibroblast-like synoviocytes. J Biol Chem 1998;273:7620-7627 (Pubitemid 28152789)
13. Miyazawa K, Mori A, Yamamoto K, Okudaira H. Constitutive transcription of the human interleukin-6 gene by rheumatoid synoviocytes: spontaneous activation of NF-κB and CBF1. Am J Pathol 1998;152:793-803. (Pubitemid 28110726)
14. Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998;28:197-208. (Pubitemid 29027651)
15. Firestein GS. NF-κB: holy grail for rheumatoid arthritis? [editorial]. Arthritis Rheum 2004;50:2381-2386
16. Miagkov AV, Kovalenko DV, Brown CE, Didsbury JR, Cogswell JP, Stimpson SA, et al. NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci U S A 1998;95:13859-13864
17. Makarov SS. NF-κB in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res 2001;3:200-206
18. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002;109 Suppl:S81-96. (Pubitemid 34457854)
19. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev 2004;18: 2195-2224
20. Perkins ND, Gilmore TD. Good cop, bad cop: the different faces of NF-κB. Cell Death Differ 2006;13:759-772
21. Campbell KJ, Perkins ND. Post-translational modification of RelA(p65) NF-κB. VI. Biochem Soc Trans 2004;32:1087-1089
22. Vermeulen L, Vanden Berghe W, Haegeman G. Regulation of NF-κB transcriptional activity. Cancer Treat Res 2006;130:89-102.
23. Vanden Berghe W, Plaisance S, Boone E, De Bosscher K, Schmitz ML, Fiers W, et al. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-κB p65 transactivation mediated by tumor necrosis factor. J Biol Chem 1998;273:3285-3290 (Pubitemid 28109741)
24. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G. Transcriptional activation of the NF-κB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 2003;22:1313-1324 (Pubitemid 36362695)
25. Jamaluddin M, Wang S, Boldogh I, Tian B, Brasier AR. TNF-α- induced NF-κB/RelA Ser(276) phosphorylation and enhanceosome formation is mediated by an ROS-dependent PKAc pathway. Cell Signal 2007;19:1419-1433
26. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001;11:372-377 (Pubitemid 32900529)
27. De Bosscher K, Vanden Berghe W, Haegeman G. Nuclear receptors and NF-κB. Oncogene 2006;51:6868-6886
28. Gossye V, Haegeman G, De Bosscher K. Therapeutic implications of the nuclear factor-κB/nuclear receptor cross-talk. Front Biosci 2008;13:4122-4143 (Pubitemid 351599679)
29. De Bosscher K, Schmitz ML, Vanden Berghe W, Plaisance S, Fiers W, Haegeman G. Glucocorticoid-mediated repression of nuclear factor-κB- dependent transcription involves direct interference with transactivation. Proc Natl Acad Sci U S A 1997;94:13504-13509 (Pubitemid 28009612)
30. Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFκB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 2000;14: 2314-2329
31. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 2003;24:488-522. (Pubitemid 37059110)
32. Lowenberg M, Stahn C, Hommes DW, Buttgereit F. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids 2008;73: 1025-1029
33. Lowenberg M, Verhaar AP, van den Brink GR, Hommes DW. Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. Trends Mol Med 2007;13:158-163 (Pubitemid 46498830)
34. De Bosscher K, Vanden Berghe W, Beck IM, Van Molle W, Hennuyer N, Hapgood J, et al. A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci U S A 2005;102:15827-15832 (Pubitemid 41552827)
35. Dewint P, Gossye V, De Bosscher K, Vanden Berghe W, Van Beneden K, Deforce D, et al. A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J Immunol 2008;180:2608-2615
36. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
37. Louw A, Swart P, de Kock SS, van der Merwe KJ. Mechanism for the stabilization in vivo of the aziridine precursor -(4- acetoxyphenyl)-2-chloro-N- methyl-ethylammonium chloride by serum proteins. Biochem Pharmacol 1997;53:189-197 (Pubitemid 27013474)
38. Clayton AL, Rose S, Barratt MJ, Mahadevan LC. Phosphoacetylation of histone H3 on c-fos- and c-jun-associated nucleosomes upon gene activation. EMBO J 2000;19:3714-3726 (Pubitemid 30462129)
39. Vanden Berghe W, Francesconi E, De Bosscher K, Resche-Rigon M, Haegeman G. Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor- κB-dependent mechanism. Mol Pharmacol 1999;56:797-806. (Pubitemid 29491183)
40. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254
41. Inoue T, Hammaker D, Boyle DL, Firestein GS. Regulation of JNK by MKK-7 in fibroblast-like synoviocytes. Arthritis Rheum 2006;54:2127-2135 (Pubitemid 44051068)
42. Cogswell JP, Godlevski MM, Wisely GB, Clay WC, Leesnitzer LM, Ways JP, et al. NF-κB regulates IL-1β transcription through a consensus NF-κB binding site and a nonconsensus CRE-like site. J Immunol 1994;153:712-723 (Pubitemid 2129464)
43. Natoli G, Chiocca S. Nuclear ubiquitin ligases, NF-κB degradation, and the control of inflammation. Sci Signal 2008;1:pe1.
44. Gherzi R, Trabucchi M, Ponassi M, Ruggiero T, Corte G, Moroni C, et al. The RNA-binding protein KSRP promotes decay of β-catenin mRNA and is inactivated by PI3K-AKT signaling. PLoS Biol 2006;5:e5. (Pubitemid 46129529)
45. Gossye V, Elewaut D, Van Beneden K, Dewint P, Haegeman G, De Bosscher K. A plant-derived glucocorticoid receptor modulator attenuates inflammation without provoking ligand-induced resistance. Ann Rheum Dis 2009. In press.
46. Sugiyama E, Kuroda A, Taki H, Ikemoto M, Hori T, Yamashita N, et al. Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells. J Rheumatol 1995;22:2020-2026
47. Han CW, Choi JH, Kim JM, Kim WY, Lee KY, Oh GT. Glucocorticoid-mediated repression of inflammatory cytokine production in fibroblast-like rheumatoid synoviocytes is independent of nuclear factor-κB activation induced by tumour necrosis factor α. Rheumatology (Oxford) 2001;40:267-273 (Pubitemid 32266343)
48. Zhang Y, Saccani S, Shin H, Nikolajczyk BS. Dynamic protein associations define two phases of IL-1β transcriptional activation. J Immunol 2008;181:503-512
49. Goto M, Katayama KI, Shirakawa F, Tanaka I. Involvement of NF-κB p50/p65 heterodimer in activation of the human pro-interleukin- 1β gene at two subregions of the upstream enhancer element. Cytokine 1999;11:16-28. (Pubitemid 29097348)
50. Newton R, Holden NS. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol 2007;72:799-809.
51. Toh ML, Yang Y, Leech M, Santos L, Morand EF. Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: up-regulation by interleukin-1β and glucocorticoids. Arthritis Rheum 2004;50:3118-3128 (Pubitemid 39371987)